LFA
LGND icon

LGT Financial Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

LGT Financial Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-22
Closed -$2.36K – 541
2024
Q4 		$2.36K Hold
22
– – 0.01% 670
2024
Q3 		$2.2K Hold
22
– – 0.01% 655
2024
Q2 		$1.85K Hold
22
– – ﹤0.01% 735
2024
Q1 		$1.61K Hold
22
– – ﹤0.01% 752
2023
Q4 		$1.57K Hold
22
– – ﹤0.01% 803
2023
Q3 		$1.32K Buy
+22
New +$1.45K ﹤0.01% 861

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LGT Financial Advisors's LGND Position: Q1 2025 in Review

LGT Financial Advisors sold out of Ligand Pharmaceuticals (LGND) in Q1 2025, closing a stake of 22 shares — an estimated $2.36K sold.

LGT Financial Advisors first reported a position in LGND in Q3 2023 and held it in 6 quarters. The position peaked at $2.36K in Q4 2024. 262 funds tracked by Wall St. Rank hold LGND as of Q1 2025.

  • LGT Financial Advisors reported no remaining Ligand Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • LGT Financial Advisors sold 22 Ligand Pharmaceuticals shares in Q1 2025, an estimated $2.36K.
  • LGT Financial Advisors first reported a position in Ligand Pharmaceuticals in Q3 2023 and held it in 6 quarters.
  • LGT Financial Advisors's Ligand Pharmaceuticals position peaked at $2.36K in Q4 2024.
  • 262 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2025.

Based on LGT Financial Advisors's 13F filing for Q1 2025, filed 8 May 2025.